Autosomal dominant Parkinson disease 4
MONDO:0011562A late onset Parkinson disease that has material basis in heterozygous triplication of the alpha-synuclein gene (SNCA) on chromosome 4q22.
Also known as: autosomal dominant Parkinson disease 4, autosomal dominant Parkinson disease type 4, PARK4, Parkinson disease 4, autosomal dominant, Parkinson disease 4, autosomal dominant Lewy body, autosomal dominant Parkinson's disease 4
139 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Experimental cancer drug trial halted early
Disease control TerminatedThis early-stage study tested a new drug called PF-07265807 in people with advanced or metastatic solid tumors that had spread. The main goals were to find a safe dose and check for side effects. The trial was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Immunotherapy plus radiation for early lung cancer: trial halted early
Disease control TerminatedThis phase 3 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to precise, high-dose radiation (SBRT) could help prevent early-stage non-small cell lung cancer from returning. The study enrolled 448 people with stage I or II lung cancer who could not hav…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Experimental cancer cocktails show promise, but study halted early
Disease control TerminatedThis early-stage trial tested two drug combinations—TNO155 plus spartalizumab or ribociclib—in 122 adults with advanced solid tumors like lung, head and neck, and colorectal cancers. The goal was to check safety and see if the drugs could slow cancer growth. The study was termina…
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC